LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Clowney, Billy"
  2. AU="Andrews, Lawrence C."
  3. AU="Arias, Andrés Hugo"
  4. AU="Yeo, B K"
  5. AU="Sultan, Mahmoud H"
  6. AU="Kou, Z Q"
  7. AU="Lamm, L"
  8. AU="Truxius, Lidia"
  9. AU="Xingyi Guo"
  10. AU="Gang Lin"
  11. AU="Oka, T"
  12. AU="Frank-Pearce, Summer G"
  13. AU="Hairi Li"
  14. AU="Park, SungHee"
  15. AU="Pascual-Carreras, Eudald"
  16. AU=Joffe Ari R
  17. AU="Buccafurri, Francesco"
  18. AU="Naomi H. Philip"
  19. AU="P. Naina"
  20. AU="Sigal, Leonard H"
  21. AU="Xu, T" AU="Xu, T"
  22. AU="Mazlout, Adam"
  23. AU="Novak, Cheryl B"
  24. AU="Ren, Zhongmin"
  25. AU="Nadhira Houhou-Fidouh"
  26. AU="Seiffert, Jacqui"
  27. AU=Zhang Zizhen
  28. AU="Bhupender Singh Negi"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

    Niesvizky, Ruben / Flinn, Ian W / Rifkin, Robert / Gabrail, Nashat / Charu, Veena / Clowney, Billy / Essell, James / Gaffar, Yousuf / Warr, Thomas / Neuwirth, Rachel / Zhu, Yanyan / Elliott, Jennifer / Esseltine, Dixie-Lee / Niculescu, Liviu / Reeves, James

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2015  Band 33, Heft 33, Seite(n) 3921–3929

    Abstract: Purpose: The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with myeloma.: Patients and methods: Patients (N = 502) were randomly assigned 1:1:1 to ...

    Abstract Purpose: The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with myeloma.
    Patients and methods: Patients (N = 502) were randomly assigned 1:1:1 to 24 weeks (eight 21-day cycles) of induction with bortezomib-dexamethasone (VD; n = 168; intravenous bortezomib 1.3 mg/m(2), days 1, 4, 8, and 11 plus oral dexamethasone 20 mg, days 1, 2, 4, 5, 8, 9, 11, and 12 [cycles 1 to 4], or 1, 2, 4, and 5 [cycles 5 to 8]), bortezomib-thalidomide-dexamethasone (VTD; n = 167; bortezomib and dexamethasone as before plus oral thalidomide 100 mg, days 1 to 21), or bortezomib-melphalan-prednisone (VMP; n = 167; bortezomib as before plus oral melphalan 9 mg/m(2) and oral prednisone 60 mg/m(2), days 1 to 4, every other cycle), followed by 25 weeks (five 35-day cycles) of bortezomib maintenance (1.6 mg/m(2), days 1, 8, 15, and 22). The primary end point was progression-free survival.
    Results: After 42.7 months' median follow-up, median progression-free survival with VD, VTD, and VMP was 14.7, 15.4, and 17.3 months, respectively; median overall survival was 49.8, 51.5, and 53.1 months, with no significant differences among treatments for either end point (global P = .46 and P = .79, respectively, Wald test). Overall response rates were 73% (VD), 80% (VTD), and 70% (VMP). Adverse events were more common with VTD than VD or VMP. Bortezomib maintenance was feasible without producing cumulative toxicity.
    Conclusion: Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.
    Mesh-Begriff(e) Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Community Health Services ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Multivariate Analysis ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Risk Assessment ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Treatment Outcome
    Chemische Substanzen Adrenal Cortex Hormones ; Thalidomide (4Z8R6ORS6L) ; Bortezomib (69G8BD63PP)
    Sprache Englisch
    Erscheinungsdatum 2015-11-20
    Erscheinungsland United States
    Dokumenttyp Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2014.58.7618
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1847: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.

    Boccia, Ralph / Malik, Imtiaz A / Raja, Vinay / Kahanic, Stephen / Liu, Randall / Lillie, Tom / Tomita, Dianne / Clowney, Billy / Silberstein, Peter

    The oncologist

    2006  Band 11, Heft 4, Seite(n) 409–417

    Abstract: Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin ... ...

    Abstract Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 mug) Q3W in patients with CIA. Eligible patients (> or =18 years) were anemic (hemoglobin <11g/dl), had a nonmyeloid malignancy, and were receiving multicycle chemotherapy. This analysis includes 1,493 patients who received at least one dose of darbepoetin alfa. The effect of baseline hemoglobin (<10 or > or =10 g/dl) on clinical outcomes was evaluated. Patients in the > or =10-g/dl stratum achieved the hemoglobin target range (11-13 g/dl)in less time than patients in the <10-g/dlstratum (3 weeks vs. 9 weeks). More patients in the > or =10-g/dl stratum achieved the hemoglobin target range (87% vs. 66%); however, similar proportions of patients in both strata maintained hemoglobin within the target range (73% vs. 71%). Fewer patients in the > or =10-g/dl stratum received RBC transfusions from week 5 to the end of the study (12% vs. 28%). Over 50% of patients in both strata reported clinically significant improvements (> or =3-point increase) in Functional Assessment of Cancer Therapy-Fatigue score. Twenty-eight percent of patients reported serious adverse events; 3% of all patients had a venous or arterial thrombotic event. This study demonstrates that darbepoetin alfa Q3W is well tolerated and effective for treating CIA.
    Mesh-Begriff(e) Adult ; Aged ; Aged, 80 and over ; Anemia/blood ; Anemia/chemically induced ; Anemia/drug therapy ; Antineoplastic Agents/adverse effects ; Darbepoetin alfa ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Endpoint Determination ; Erythropoietin/administration & dosage ; Erythropoietin/adverse effects ; Erythropoietin/analogs & derivatives ; Female ; Follow-Up Studies ; Hemoglobins/drug effects ; Hemoglobins/metabolism ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Quality of Life ; Time Factors ; Treatment Outcome
    Chemische Substanzen Antineoplastic Agents ; Hemoglobins ; Erythropoietin (11096-26-7) ; Darbepoetin alfa (15UQ94PT4P)
    Sprache Englisch
    Erscheinungsdatum 2006-04
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1083-7159
    ISSN 1083-7159
    DOI 10.1634/theoncologist.11-4-409
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4845: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang